

15th January, 2016

Ms. Dhaneshwari Chenani
Assistant Manager – Listing Compliance
National Stock Exchange of India Limited
Exchange Plaza, Bandra-Kurla Complex
Bandra (East),
Mumbai – 400 051

Dear Madam,

Security Code: WOCKPHARMA

Sub: Clarification on news item appeared in Business Standard

This refers to your E-mail dated 15th January, 2016 regarding news item in Business Standard titled "Wockhardt recalls 62,555 bottles of antibiotics in US".

We have to inform you that the Company has earlier decided to recall, as a part of remedial measure the remaining batches in the US market that were manufactured prior to US FDA Import Alerts even though there was no evidence of risk to patient safety from these products. The same was informed to the Stock Exchanges on 28th April, 2015 by the Company. (Copy of the said letter submitted to Stock Exchanges is enclosed for reference). The recall stated in the said news item forms part of the same.

Please note that as a part of standard practice, the Company has to inform to US FDA periodically the products actually received from the trade against such recall. Such periodic returns of products are reported by the media based on such information submitted to US FDA by the Company from time to time even though they are not additional recalls.

The Company keeps the exchange informed about events, information etc. including price sensitive information in accordance with regulatory requirements. In present case, we do not have any important information / announcement to be shared.

In the event that there is any development that requires disclosure, we will make the same in accordance with the requirements of Listing Regulations.

This is for your information and records.

For **Wockhardt Limited**



Narendra Singh
Company Secretary

Encl: As above

April 28, 2015

National Stock Exchange of India Limited
Listing Department, Exchange Plaza
Bandr Kurla Complex, Bandra (East)
Mumbai – 400 051

Fax No. 022- 26598237 / 38

NSE Symbol – WOCKPHARMA

Dear Sir,

During the last US FDA cGMP inspection of the facilities at L1- Chikalthana and Waluj in Aurangabad, Maharashtra, some observations were reported pertaining to batches of some products manufactured prior to the US FDA Import Alerts.

Whereas the Company continues to supply some of the products in the US market manufactured in the same facilities, several batches of other products, manufactured prior to the Import Alerts may still be in the US market.

As a measure of preparedness and as an abundant precaution, the Company has now decided to recall, as a part of remedial measure all the remaining batches in the US market that were manufactured prior to the US FDA Import Alerts even though there is no evidence of risk to patient safety from the products currently available in the US market.

Additionally, the MHRA, UK has restored the EU GMP certification of our potent product facility at Kadaiya, Daman.

As per clause 36 of the Listing Agreement the company keeps the exchange informed about events, information etc. including price sensitive information in accordance with regulatory requirement.

This is for your information and record.

Yours Cordially,

For **Wockhardt Limited**



Amruta Avasare
Assistant Company Secretary